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Rett syndrome (RTT) is an X-linked dominant neurodevelopmental disorder affecting 1/10,000–15,000 girls. The
disease-causing gene was identified as MECP2 on chromosome Xq28, and mutations have been found in ∼80%
of patients diagnosed with RTT. Numerous mutations have been identified in de novo and rare familial cases, and
they occur primarily in the methyl-CpG–binding and transcriptional-repression domains of MeCP2. Our first
diagnostic strategy used bidirectional sequencing of the entireMECP2 coding region. Subsequently, we implemented
a two-tiered strategy that used denaturing high-performance liquid chromatography (DHPLC) for initial screening
of nucleotide variants, followed by confirmatory sequencing analysis. If a definite mutation was not identified, then
the entire MECP2 coding region was sequenced, to reduce the risk of false negatives. Collectively, we tested 228
unrelated female patients with a diagnosis of possible (209) or classic (19) RTT and found MECP2 mutations in
83 (40%) of 209 and 16 (84%) of 19 of the patients, respectively. Thirty-two different mutations were identified
(8 missense, 9 nonsense, 1 splice site, and 14 frameshifts), of which 12 are novel and 9 recurrent in unrelated
patients. Seven unclassified variants and eight polymorphisms were detected in 228 probands. Interestingly, we
found that T203M, previously reported as a missense mutation in an autistic patient, is actually a benign poly-
morphism, according to parental analysis performed in a second case identified in this study. These findings highlight
the complexities of missense variant interpretation and emphasize the importance of parental DNA analysis for
establishing an etiologic relation between a possible mutation and disease. Overall, we found a 98.8% concordance
rate between DHPLC and sequence analyses. One mutation initially missed by the DHPLC screening was identified
by sequencing. Modified conditions subsequently enabled its detection, underscoring the need for multiple optimized
conditions for DHPLC analysis. We conclude that this two-tiered approach provides a sensitive, robust, and efficient
strategy for RTT molecular diagnosis.
Introduction
Rett syndrome (RTT [MIM 312750]) is an X-linked
dominant neurodevelopmental disorder and a significant
genetic cause of mental retardation, affecting 1/10,000–
15,000 girls (Rett 1966; Hagberg et al. 1983; Hagberg
1985; Schanen and Francke 1998). Patients with classic
RTT appear to develop normally until age 6–18 mo, at
which time they enter a period of neurodevelopmental
regression. Symptoms include gradual loss of speech and
purposeful hand use, development of microcephaly, sei-
zures, ataxia, autistic features, intermittent hyperventi-
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lation, and stereotypic hand movements. The condition
subsequently stabilizes, with patients usually surviving
into adulthood (Hagberg et al. 1983). The RTT gene on
Xq28 was identified as MECP2, which encodes the
methyl-CpG–binding protein 2 that is normally involved
in transcriptional silencing (Amir et al. 1999 [GenBank
accession number X99686]). Numerous studies have
since found various mutations (missense, nonsense, and
frameshifts) in the coding region of MECP2 in patients
with RTT, identifying mutations for as many as 80% of
patients (Amir et al. 1999, 2000; Wan et al. 1999;
Amano et al. 2000; Bienvenu et al. 2000; Cheadle et al.
2000; Hampson et al. 2000; Huppke et al. 2000; Kim
and Cook 2000; Obata et al. 2000; Orrico et al. 2000;
Xiang et al. 2000); the remaining 20% may have mu-
tations in other regions of this gene, such as regulatory
elements and noncoding regions, but this remains to be
determined. Most mutations lie within the methyl-
CpG–binding (MBD) or transcriptional-repression (TRD)
functional domains. In addition, a number of deletions
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Table 1
Primer Sequences Used for PCR and Dye-Terminator Sequencing
Exon Sequence
Fragment Size
(bp)
PCR primers:
2-For U-TAA GCT GGG AAA TAG CCT AGT AC 454
2-Rev R-TTA TAT GGC ACA GTT TGG CAC AG
3-For U-AGG ACA TCA AGA TCT GAG TGT AT 662
3-Rev R-GGT CAT TTC AAG CAC ACC TG
4a-For U-CGA GTG AGT GGC TTT GGT GA 715
4a-Rev R-ACA GAT CGG ATA GAA GAC TCC TT
4a-For.2 U-CGC TCT GCC CTA TCT CTG A 620
4b-For.3 U-GGC AGG AAG CGA AAA GCT GAG 402
4b-Rev.3 R- TGA GTG GTG GTG ATG GTG GTG G
4c/d-cFor U-GGA AAG GAC TGA AGA CCT GTA AG 408
4c/d-dRev R-CTC CCT CCC CTC GGT GTT TG
4e-For U-GGA GAA GAT GCC CAG AGG AG 447
4e-Rev R-CGG TAA GAA AAA CAT CCC CAA
U (21 M13 primer tail) TGT AAA ACG ACG GCC AGT
R (M13 reverse tail) CAG GAA ACA GCT ATG ACC
Dye-terminator sequencing primers:
2-Rev.2 CTA AAA AAA AAA AAA GGA AGG TTAC
4c-For.S AGC CCT GGG CGG AAA AGC
4d-Rev.S TAC TTT TCT GCG GCC GTG
have been identified within a limited region, which sug-
gests a potential recombinational hotspot in the last exon
of the gene. A number of mutations recur in unrelated
patients, reflecting the hypermutability of certain sites.
It is noteworthy that MECP2 mutations have also been
found to cause a variety of phenotypes other than classic
RTT, ranging from very mild mental retardation to se-
vere neonatal encephalopathy in boys born into kindreds
with RTT (Wan et al. 1999; Orrico et al. 2000).
Many methods for detecting mutations have been de-
scribed, and strengths and limitations are inherent in
each technique (Cotton 1997). Because DNA-sequence
analysis is considered to be the gold standard for the
identification of point mutations or deletion/insertion
mutations that involve a few bases, DNA diagnostic
testing was initially set up by PCR-based direct sequenc-
ing of the MECP2 coding region, using automated flu-
orescence methods. Nevertheless, we thought that the
RTT diagnostic test could be made more efficient by
use of a robust method to scan patient samples for se-
quence variations/mutations prior to targeted sequence
analysis. Denaturing high-performance liquid chroma-
tography (DHPLC) is such a method. A highly sensitive
PCR-based technique for nucleotide variant detection,
DHPLC relies on the principle of heteroduplex analysis
by ion-pair reverse-phase liquid chromatography under
partially denaturing conditions (Oefner and Underhill
1995, 1998; Liu et al. 1998; O’Donovan et al. 1998).
We thus devised a two-tiered molecular diagnostic ap-
proach for RTT, to increase test efficiency while main-
taining the sensitivity provided by sequence analysis.
The technical strategy and our cumulative results are
presented in this article.
Material and Methods
Patient Material
Genomic DNA from patients with RTT with a pre-
viously identified mutation in theMECP2 coding region
was used as positive control material for the develop-
ment of DNA diagnostic tests (Amir et al. 1999, 2000;
R. E. Amir and H. Y. Zoghbi, unpublished data). We
tested 209 female patients with possible RTT and 19
with a diagnosis of classic RTT (as determined by the
referring clinicians), whose blood samples were submit-
ted to the Baylor DNA Diagnostic Laboratory. Genomic
DNA was extracted from blood leukocytes using the
Puregene DNA isolation kit (Gentra Systems) or the
QIAamp DNA Blood kit (Qiagen), following the man-
ufacturer’s instructions.
PCR Amplification
PCR primers (table 1) were designed to amplify
MECP2 coding exons 2, 3, and 4, using a total of six
reactions (these were exons 1, 2, and 3 before the recent
discovery of a new 5′ UTR exon [Reichwald et al. 2000]).
Primers for coding exons 2 and 3 correspond to flanking
intron sequences. Exon 4 was amplified as four over-
lapping fragments (4a, 4b, 4cd, and 4e) that collectively
span the 5′ intronic sequence and 3′ UTR sequences. Two
forward primers were used to amplify exon 4a: the exon
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4a-For primer (used for sequencing) was redesigned as
exon 4a-For.2 (used for DHPLC), to prevent upstream
polymorphisms from interfering with DHPLC analysis.
Both primers are used in combination with the exon 4a-
Rev primer. Primers (Gibco BRL) were synthesized with
universal M13 tails (21M13 or M13 reverse), to fa-
cilitate direct sequencing using dye-primer chemistry (see
table 1). PCR reactions were carried out in 50-ml reaction
volumes containing 100 ng genomic DNA, 1# PCR
buffer (50 mM KCl, 10 mM Tris HCl [pH 8.3], 1.5 mM
MgCl2, and 0.001% w/v gelatin; Perkin Elmer), 0.05
mM dNTP, 1.88 pmol of each primer, and 1.25 U Taq
polymerase (Perkin Elmer). The exon 4c/d PCR reaction
mix contained 1 mM MgCl2 and 4.69 pmol of each
primer. PCR conditions included an initial denaturation
at 94C for 2 min 30 s, followed by 10 “step-down”
cycles of 30 s at 94C, 30 s at 65C (decreasing 1.5C
per cycle), and 1 min 45 s at 72C, followed by 28 cycles
of 30 s at 94C, 30 s at 51C, and 1 min 30 s at 72C,
and a final extension step at 72C for 5 min.
DHPLC Analysis
Heteroduplex formation was induced by heat dena-
turation of PCR products at 94C for 5 min, followed
by gradual reannealing from 94C to 25C over 45 min.
DHPLC analysis was performed with the WAVE DNA-
fragment analysis system (Transgenomic). PCR products
(10 ml per sample) were eluted at a flow rate of 0.9 ml/
min with a linear acetonitrile gradient. The values of the
buffer gradients (buffer A, 0.1 M triethylammoniuma-
cetate; buffer B, 0.1M triethylammoniumacetate/25%
acetonitrile), start and end points of the gradient, and
melting temperature predictions were determined by
WAVEMAKER software (Transgenomic). Analysis per
sample took ∼7.5 min, including regeneration and re-
equilibration to the starting conditions. Optimal run
temperatures were empirically determined;mobile-phase
temperatures were assessed within a 5C window above
and below the suggested run temperature on the basis
of each fragment’s characteristic melting profile. Run
temperatures that allowed detection of all tested se-
quence variants were 59C for exon 2; 61C, 63C, 66C,
and 67C for exon 3; 61C, 64C, and 66C for exon
4a; 64C and 65C for exon 4b; 65C and 66C for exon
4c/d; and 60C, 63C, and 65C for exon 4e. Data anal-
ysis was based on visual inspection of the chromato-
grams, and comparison with normal controls was in-
cluded in each run. Heterozygous profiles were detected
as distinct elution peaks from homozygous wild-type
peaks.
Direct Sequencing Analysis
PCR products used for sequencing analysis were pu-
rified using the QIAquick PCR purification kit (Qiagen)
and bidirectionally sequenced using the ABI Prism
BigDye Primer Cycle Sequencing Ready Reaction kit (PE
Biosystems). The BigDye Terminator Cycle Sequencing
Ready Reaction kit (PE Biosystems) was used to se-
quence the exon 2 reverse reaction and the exon 4c/d
forward and reverse reactions (primers listed in table 1).
Samples were analyzed on an ABI 377 DNA sequencer
(PE Biosystems), according to the manufacturer’s in-
structions. Patient sequence data from both orienta-
tions were aligned for comparison with corresponding
wild-type sequence using SEQUENCHER 3.0 analysis
software.
Our two-step diagnostic strategy calls for targeted se-
quence analysis of a specific region for samples that are
positive by DHPLC analysis. For samples that are neg-
ative by DHPLC analysis or are not found to have a de-
finitive mutation by targeted sequence analysis (poly-
morphism or unclassified variant alleles), direct sequenc-
ing of the entire MECP2 coding region is performed, to
reduce the risk of false negatives.
Results
MECP2 Mutation Detection by Direct Sequence
Analysis
Mutation analysis for RTT was initially set up using
bidirectional sequencing of PCR products corresponding
to the MECP2 coding region. Dye-primer sequencing
chemistry was used, except for several dye-terminator
sequencing reactions required for technical reasons
(exon 2 reverse and exon 4c/d forward and reverse re-
actions). Control samples used in our assay validation
included 11 previously characterized DNA samples from
patients with a diagnosis of classic RTT and from un-
affected family members (Amir et al. 1999, 2000; R. E.
Amir and H. Y. Zoghbi, unpublished data). Sequence
analysis, in accordance with our protocol, was per-
formed in a blinded manner, and 11 of 11 control sam-
ples were correctly identified as mutant, polymorphic,
or negative.
Diagnostic sequencing was performed on the first 142
patients referred to the Baylor DNA Diagnostic Labo-
ratory with a definite or possible diagnosis of RTT. Se-
quence variations were observed in 65 of 142 patients.
Of these, 62 (44%) were positive for a disease-causing
MECP2 mutation. A mutation was considered disease-
causing under either of the following conditions: (1) it
had already been reported in the literature as a de novo
mutation in a patient with RTT or (2) it was a truncating
mutation that disrupted gene function (nonsense, splice-
site mutation, insertion, or deletion frameshift). In three
individuals (2%) who were heterozygous for an unclas-
sified sequence variant, analysis of both parents was rec-
ommended to define each variant as either a de novo
Buyse et al.: Diagnostic Testing for Rett Syndrome 1431
Figure 1 DHPLC elution profiles for twoMECP2 coding-region
mutations detected in two patients with sporadic RTT. A, Relevant
exon 3 elution profiles (63C) for a normal individual and a patient
carrying the R106W mutation. The DHPLC profiles are superimposed
to illustrate differences. The direct sequencing result illustrates the
corresponding 316CrT nucleotide substitution. B, Relevant exon 4b
elution profiles (64C) for a normal individual and a patient carrying
the S360X mutation. The direct sequencing result illustrates the cor-
responding 1079CrA nucleotide substitution.
Table 2
Different Phases Involved in the Development of a Two-Step Protocol for RTT Testing by DHPLC
and Bidirectional Direct Sequencing Analysis
TEST DATA
NO. (%)
Positive Unclassified Negative
Bidirectional direct sequencing (142 cases) 62 (44) 3 (2) 77 (54)
DHPLC analysis validation:
Validation phase 1 (15 samples tested blindlya) 10 5
Validation phase 2 (36 cases tested in parallela) 19 17
DHPLC and bidirectional direct sequencing (86 casesb) 37 (43) 2 (2) 47 (55)
a 100% concordance.
b 98.8% concordance: one case DHPLC negative and sequencing positive.
mutation or a benign polymorphism. The remaining 77
cases (54%) were negative by sequencing (see table 2).
MECP2 Mutation Detection by DHPLC Analysis
We evaluated DHPLC for its potential as a screen-
ing method to reduce the need for sequencing the com-
plete coding region in almost half of our caseload. PCR
heteroduplexes are resolved from homoduplexes on a
DHPLC column via differential elution profiles under
partially denaturing conditions. We optimized DHPLC
run conditions with the aid of WAVEMAKER software
and by empiric determination using 50 positive control
samples (see Material and Methods section) that in-
cluded mutations (base substitutions, insertions, or de-
letions), polymorphisms, and unclassified missense var-
iants in exons 3 and 4. Because no exon 2 mutations
have been identified at this institution to date, exon 2
run conditions were based on software prediction. Exons
3 and 4 contain multiple melting domains, so multiple
run temperatures were used to analyze PCR fragments
in these regions. All 50 sequence variants were identified,
under one or more run conditions, as unique elution
profiles. Examples of variant DHPLC chromatograms
and their confirmatory sequences are shown in figure 1.
The validation of MECP2 coding-region analysis by
DHPLC consisted of two phases. For the first phase, a
set of 15 samples that were previously tested by sequence
analysis were analyzed by DHPLC in a blinded manner.
DHPLC analysis of the entire MECP2 coding yielded
100% concordance with prior sequencing data (10 pos-
itives and 5 negatives; see table 2). In the second phase
of DHPLC validation, 36 samples that were being ex-
amined by sequence analysis in our laboratory were
tested in parallel by DHPLC. Nineteen samples were
found to carry one or more sequence variations and 17
were negative, which yielded 100% concordance be-
tween both methods (table 2).
On the basis of these results, a two-tiered molecular
diagnostic strategy was adopted. Our current testing
strategy entails that we first analyze all MECP2 coding
exons by DHPLC. PCR fragments encoding a sequence
variant are further analyzed by bidirectional sequencing.
For samples that are negative by initial DHPLC analysis
or are found to carry a polymorphism or unclassified
sequence variant, the entire MECP2 coding region is
analyzed by bidirectional sequencing. This strategy
proved to be both efficient and robust. Eighty-six cases
1432 Am. J. Hum. Genet. 67:1428–1436, 2000
Table 3
MECP2 Mutations Detected by DHPLC and Direct Sequencing Analysis
Mutation Type
and Exon Nucleotide Change Amino Acid Change Domain
No. of Patients
(This Lab) Reference
Missense:
3 317 GrA R106Q MBD 2 Bienvenu et al. (2000)
3 316 CrT R106W MBD 3 Amir et al. (1999)
4 397 CrT R133C MBD 1 Amir et al. (1999)
4 455 CrG P152R MBD 1 Cheadle et al. (2000)
4 464 TrC F155S MBD 1 Amir et al. (1999)
4 473 CrT T158M MBD 21 Amir et al. (1999)
4 916 CrT R306C TRD 8 Wan et al. (1999)
4 917 GrA R306H TRD 1 Cheadle et al. (2000)
Nonsense:
4 423 CrG Y141X MBD 1 Amir et al. (2000)
4 430 ArT K144X MBD 1 This study
4 502 CrT R168X 13 Wan et al. (1999)
4 508 CrT Q170X 1 Amir et al. (2000)
4 611 CrG S204X 1 This study
4 763 CrT R255X TRD 12 Amir et al. (1999)
4 808 CrT R270X TRD 8 Cheadle et al. (2000)
4 880 CrT R294X TRD 7 Cheadle et al. (2000); Xiang et al. (2000)
4 1079 CrA S360X 1 This study
Splice site IVS2-2 ArG 1 Huppke et al. (2000); Amir et al. (2000)
Frameshift:
4 553delG 1 This study
4 705delG TRD 1 Amir et al. (2000)
4 750delC TRD 1 This study
4 749insCC TRD 1 This study
4 803delG TRD 2 Wan et al. (1999)
4 807delC TRD 1 Obata et al. (2000)
4 965del6nt/ 1026insG/
1138del71nt
Complex deletion/ insertion 1 This study
4 1118del183nt/ ins61nt Complex deletion/ insertion 1 This study
4 1157del41nt 1 Cheadle et al. (2000)
4 1161del6nt/ 1177del26nt Complex deletion 1 This study
4 1163del26nt 1 Bienvenu et al. (2000)
4 1163del11nt/
1174del18nt
Complex deletion 1 This study
4 1164del44nt 1 This study
4 1308delTC 1 This study
have been analyzed using this strategy (see table 2). Mu-
tations were identified in 37 cases (43%), 2 cases (2%)
had unclassified variants, and 47 cases (55%) were neg-
ative. The DHPLC results were consistent with sequenc-
ing analysis in 98.8% of these cases. One patient was
initially negative by DHPLC analysis, but direct se-
quencing of the complete MECP2 coding region of this
patient revealed an unclassified missense substitution in
exon 3 (S86C). This substitution was missed by DHPLC,
despite the use of three different temperatures (61C,
63C, and 66C), causing a false negative rate of 1.2%.
The region encoding amino acids 85–90 is very GC rich
but was anticipated to melt at 66C. Reanalysis by
DHPLC allowed detection of this specific variant at 67C
(but not at 66C). This temperature was subsequently
added to the current set of running conditions (see the
Material and Methods section).
MECP2 Sequence Variations Detected
Our laboratory tested a total of 228 unrelated female
patients with a diagnosis of possible (209) or classic (19)
RTT for MECP2 mutations. Table 3 lists all the iden-
tified mutations, and table 4 lists the polymorphic and
unclassified sequence variations detected in this group
of patients. Disease-causing mutations were detected in
83 (40%) of 209 and 16 (84%) of 19 patients with
possible and classic sporadic RTT, respectively. A total
of 32 different mutations are reported, of which 12 are
novel (3 nonsense and 9 frameshift mutations; table 3).
These novel frameshifts included two complex deletion
and two complex deletion/insertion mutations. These
mutations were verified by comparison of forward and
reverse strands, and sequence analysis of the mutant al-
lele exclusively in cases of large deletions. Nine muta-
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Figure 2 Familial sequence analysis for the T203M polymor-
phism. Direct-sequencing results illustrate the presence of the 608CrT
nucleotide substitution in the affected patient (heterozygous) and in
her clinically unaffected father (hemizygous) but not in her unaffected
mother.
Table 4
MECP2 Polymorphisms and Unclassified Sequence Variants Detected by DHPLC and Direct Sequencing Analysis
Variant and Exon
Nucleotide
Change
Amino Acid
Change Domain
No. of Patients
(This Lab) Reference
Polymorphism:
3 375 CrA I125 MBD 1 Cheadle et al. (2000)
4 582 CrT S194 2 Amir et al. (2000)
4 608 CrT T203M 1 Orrico et al. (2000)
4 843 CrT A281 TRD 1 This study
4 984 CrT L328 1 This study
4 1189 GrA E397K 1 Wan et al. (1999)
4 1233 CrT S411 6 Amir et al. (1999)
4 1330 GrA A444T 2 This study
Unclassified:
3 257 CrG S86C MBD 1 This study
3 298 CrG L100V MBD 1 This study
4 859 GrC A287P TRD 1 This study
4 871 TrG S291Aa TRD 1 This study
4 914 ArG K305R TRD 1 This study
4 1234 GrA V412Ia 1 This study
4 1164del9nt (in-frame del) 1 This study
a Probable polymorphism, occurring in a patient who also carried a classified MECP2 mutation.
tions recurred in 77% of our patients bearing aMECP2
mutation (table 3).
A total of eight polymorphisms (five silent and three
missense) were detected in 15 patients (table 4). S194,
S411, and A444T appear to be more common, recurring
two, six, and two times, respectively. Of 15 patients with
polymorphisms, 12 were found to carry a disease-caus-
ing mutation together with the polymorphism, although
the chromosomal phase was not set. Seven unclassified
sequence variants were found, for which parental anal-
ysis was recommended. Although parental samples were
not available, two of these unclassified variants are con-
sistent with being polymorphisms (S291A and V412I),
since they were identified in patients who also had en-
coded a classified MECP2 mutation.
Parental analysis performed in two cases strongly in-
dicates that the T203M and A444T alleles are benign
polymorphisms, because the unaffected father carried
the missense variant found in the affected child. Of par-
ticular interest is one case in which the patient was found
to carry both the R106Q and T203M variant alleles.
Because neither missense allele had been reported in the
literature at the time, we requested parental samples for
further analysis, to help classify the alleles as mutant or
polymorphic. The R106Q allele was not found in either
unaffected parent and was interpreted to be a de novo
mutation. Our findings were subsequently confirmed by
a published report of another de novo R106Q mutation
in a typical case of RTT (Bienvenu et al. 2000). In con-
trast, our parental analysis of the T203M allele was
consistent with a benign polymorphism. Figure 2 shows
the sequencing data for this family, which demonstrate
that T203M is present in both the proband and her
clinically unaffected father.
Prenatal Diagnosis
Our laboratory has performed four prenatal tests thus
far. A mutation (R106W, P152R, R168X, and R294X)
was identified in the index case for each family. Subse-
quent analysis of maternal DNA by DHPLC and by
direct sequencing of the PCR fragment of interest sug-
gested that the mutation arose de novo in each case,
although germline mosaicismwas not excluded. Prenatal
diagnosis by DHPLC and direct sequencing performed
on amniotic fluid and cultured amniocytes was negative
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for the mutation in all four cases. Maternal cell contam-
ination was ruled out by PCR analysis of short-tandem
repeats at other loci.
Discussion
This article presents the mutation data accumulated
from our diagnostic laboratory experience, which in-
cludes testing of 228 unrelated patients with a diagnosis
of possible (209) or classic (19) RTT. Disease-causing
mutations were detected in 84% of patients with clas-
sical sporadic RTT, which is consistent with the estimate
reported in the literature. That only 40% of the patients
suggestive for RTT were positive forMECP2 mutations
reflects the clinical heterogeneity of these patients, who
were referred from different sources. Since mutation
analysis has focused largely on the MECP2 coding re-
gion, any large rearrangements and/or mutations that
might exist in the regulatory and noncoding regions are
not addressed. Nonetheless, the existing data from re-
search and diagnostic laboratories demonstrate that
MECP2 coding-region mutations account for the ma-
jority of classic RTT. We found a total of 32 different
mutations (table 3), including 12 novel MECP2 cod-
ing-region mutations. Nine of these are novel frameshift
mutations, with the majority located in the last exon.
Furthermore, four of these novel frameshifts involve
complex insertion and/or deletion mutations in exon 4.
These findings are consistent with the region being a
recombinational hotspot containing palindromic and
quasipalindromic sequences (Amano et al. 2000; Amir
et al. 2000; Bienvenu et al. 2000; Cheadle et al. 2000;
Huppke et al. 2000; Xiang et al. 2000). We identified
nine mutations that recurred in 77% of our mutation-
positive patients (table 3). Seven of these recurrent mu-
tations (R106W, T158M, R306C, R168X, R255X,
R270X, and R294X) involve CrT transitions at CpG
dinucleotides (Wan et al. 1999; Amano et al. 2000; Amir
et al. 2000; Bienvenu et al. 2000; Cheadle et al. 2000;
Hampson et al. 2000; Huppke et al. 2000; Obata et al.
2000). We also found eight MECP2 sequence polymor-
phisms and seven unclassified MECP2 missense vari-
ants for which parental analyses were recommended (ta-
ble 4).
Parental analysis strongly suggested that two mis-
sense variants identified in this study, A444T and
T203M, are polymorphisms; the variant allele was
found in the clinically unaffected father. Our findings
are particularly relevant for the T203M allele, which
was recently reported as a disease-causing mutation in
a girl who was initially diagnosed with autism and sub-
sequently characterized as having variant RTT with au-
tistic features (Orrico et al. 2000). This patient had been
adopted, so parental analysis could not be performed;
instead, analysis was performed on 200 normal chro-
mosomes, which were apparently negative for T203M.
The authors concluded that T203M is a novel missense
mutation associated with an atypical RTT phenotype
(Orrico et al. 2000). In retrospect, the fact that the
threonine 203 residue is not evolutionarily conserved in
MeCP2 provided a clue that this could be a benign
polymorphism. Moreover, our patient with the T203M
polymorphism was also found to carry a de novo
R106Q mutation (table 3; Bienvenu et al. 2000). Our
collective findings reclassify T203M as a polymorphism
and highlight the need for caution in the clinical inter-
pretation of sequence variants, such as missense alleles,
that may or may not be disease associated. T203M ap-
pears to be a rare polymorphic allele, since we did not
find it in the other 455 patient chromosomes we tested,
and it was not found in 200 normal chromosomes (Or-
rico et al. 2000). Further molecular investigation, in-
cluding parental analysis, would be required for allele
classification in such cases.
This two-tiered approach has a number of advantages
over our original sequencing protocol. It is less labor
and reagent intensive than fluorescent gel sequencing,
and testing efficiency is increased by prescreening pa-
tient samples by DHPLC prior to targeted sequence
analysis (the amount of sequencing was reduced by a
factor of six for the 40% of cases in which we detected
mutations). On the basis of our experience, the oper-
ational cost of MECP2 mutation analysis by this com-
bined strategy is ∼14% lower than full-sequence anal-
ysis. Comparisons were based on reagent and labor
costs specific to each assay and did not include the costs
of equipment, repeat testing, or sample processing com-
mon to both assays (e.g., DNA preparation and labo-
ratory overhead). On the basis of our detection rate and
sample volumes over a 1-year period, reagent costs were
estimated to be 9% less for the combined DHPLC and
targeted-sequencing strategy than those for full-se-
quence analysis alone. Personnel efficiency is also im-
proved: our combined approach requires 26 techni-
cian h/wk versus 32 h for full sequencing of an average
weekly caseload. This translates into a 19% reduction
in labor, or almost 1 technician d/wk. The actual cost
per test will vary given the different sample volumes,
rate of repeat testing, and overhead cost structures
among laboratories. Apart from increased cost effi-
ciency, the diagnostic testing strategy combining
DHPLC and direct sequencing has proved to be a sen-
sitive and efficient method for MECP2 mutation anal-
ysis. The sensitivity of this combined approach is equal
to or greater than that of sequencing. Mutation-positive
samples were initially identified by DHPLC in all but
one case (see table 2). Any variants that could be missed
by DHPLC would be identified by sequence analysis of
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the completeMECP2 coding region, which is prescribed
for all samples that test negative by DHPLC. Likewise,
samples that test positive by DHPLC and are found to
have a polymorphism or unclassified variant by targeted
sequencing are subsequently sequenced for the complete
coding region, further reducing the risk for false neg-
atives. Negative samples benefit from routine analysis
by two sensitive and independent methods, so the sen-
sitivity of the combined approach may be greater than
that of sequencing alone. The collective data from our
first 86 cases demonstrate the strength of this approach.
Further advantages of DHPLC include computer-as-
sisted determination of analytical conditions and au-
tomated sample-handling features. Nevertheless, mu-
tation detection is dependent on the complexity of each
fragment’s sequence-specific melting profile and the op-
timization of DHPLC analytical conditions for each spe-
cific fragment. This fact was brought to the forefront
by our experience with one patient, who tested negative
by DHPLC analysis but was positive for a novel mis-
sense variant (S86C) by sequencing, despite the use of
three different DHPLC temperature conditions for that
fragment. Temperature conditions had been determined
by a combination of computer software predictions and
empirical data that used available positive controls. Al-
though four different variants were tested during de-
velopment of the DHPLC run conditions for exon 3
(L100V, R106W, R106Q, and I125), these were located
slightly downstream of S86C. Nevertheless, software
predictions suggested that sequence alterations in this
region would be detected. When repeat analysis of this
patient’s sample revealed that 67C rather than 66C
allowed detection of the S86C variant, we added this
temperature to the DHPLC run conditions.
Improvements in the melting-profile software should
increase sensitivity and facilitate the use of DHPLC for
diagnostic testing of unknown mutations in any given
region of interest. DHPLC analysis may not detect ho-
mozygous or hemizygous point mutations without mix-
ing equal amounts of test and control samples to induce
heteroduplex formation. This would mean that samples
from boys with possible atypical RTT should be se-
quenced entirely, a policy currently followed in this lab-
oratory. In sum, we conclude that the use of DHPLC
as an initial screening tool is ideal forMECP2mutation
analysis. The two-tiered strategy combining DHPLC
with direct sequence analysis provides a robust and ef-
ficient means of molecular diagnostic testing for RTT.
No current analytical method, including sequence anal-
ysis, has 100% detection under all conditions. The chal-
lenge for molecular diagnostics is to maximize assay
sensitivity, which can be accomplished by optimizing
and combining appropriate analytical methods.
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